The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.

For a true AI-native product, extremely high margins might indicate it isn't using enough AI, as inference has real costs. Founders should price for adoption, believing model costs will fall, and plan to build strong margins later through sophisticated, usage-based pricing tiers rather than optimizing prematurely.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

A powerful, overlooked competitive moat exists in the "outsourced R&D" model. These companies, like Core Labs in energy or Christian Hansen in food, become so integral to clients' innovation that they command high margins and valuations that appear expensive when viewed only through the lens of their specific industry.

Unlike SaaS, where high gross margins are key, an AI company with very high margins likely isn't seeing significant use of its core AI features. Low margins signal that customers are actively using compute-intensive products, a positive early indicator.

Many AI startups prioritize growth, leading to unsustainable gross margins (below 15%) due to high compute costs. This is a ticking time bomb. Eventually, these companies must undertake a costly, time-consuming re-architecture to optimize for cost and build a viable business.

Traditional SaaS metrics like 80%+ gross margins are misleading for AI companies. High inference costs lower margins, but if the absolute gross profit per customer is multiples higher than a SaaS equivalent, it's a superior business. The focus should shift from margin percentages to absolute gross profit dollars and multiples.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.

The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.